<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781114</url>
  </required_header>
  <id_info>
    <org_study_id>JS002-003</org_study_id>
    <nct_id>NCT04781114</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Efficacy and Safety of JS002 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized,&#xD;
      double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as&#xD;
      immunogenicity of JS002 treated repeatedly in patients with hyperlipidemia when combined with&#xD;
      statin therapy.&#xD;
&#xD;
      In this study, two dose group (150 mg, 300 mg) were set up in this study. 750 subjects are&#xD;
      plan to be enrolled (the study drug will be assigned to a 2:1 ratio of JS002 or placebo).&#xD;
&#xD;
      Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks&#xD;
      of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>at Week 24</time_frame>
    <description>Percentage change in LDL-C relative to baseline at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>at week 24</time_frame>
    <description>The absolute change in LDL-C relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with LDL-C standard</measure>
    <time_frame>at week 24</time_frame>
    <description>The proportion of subjects with LDL-C standard in each cardiovascular disease risk stratification at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with LDL-C standard</measure>
    <time_frame>at week 52</time_frame>
    <description>The proportion of subjects with LDL-C standard in each cardiovascular disease risk stratification at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>at week 24</time_frame>
    <description>The occurrence of adverse events at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The occurrence of adverse events through study completion, an average of 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JS002 anti-drug antibody/neutralizing antibody</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Time of JS002 anti-drug antibody/neutralizing antibody in the entire trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JS002 anti-drug antibody/neutralizing antibody</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Ratio of JS002 anti-drug antibody/neutralizing antibody in the entire trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Hyperlipemia</condition>
  <arm_group>
    <arm_group_label>JS002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS002</intervention_name>
    <description>JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.</description>
    <arm_group_label>JS002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A limited list of criteria for selection of participants in the clinical study, provided in&#xD;
        terms of inclusion and exclusion criteria and suitable for assisting potential participants&#xD;
        in identifying clinical studies of interest. Use a bulleted list for each criterion below&#xD;
        the headers &quot;Inclusion Criteria&quot; and &quot;Exclusion Criteria&quot;. (Limit: 15,000 characters.)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Age 18~80 years old;&#xD;
&#xD;
          3. Stable optimized LLT at least 4 weeks before randomization;&#xD;
&#xD;
          4. At the time of screening, Low-density lipoprotein cholesterol (LDL-C) level according&#xD;
             to ASCVD risks:&#xD;
&#xD;
               -  extra high risk patients: LDL-C≥1.4mmol/L(55mg/dL)&#xD;
&#xD;
               -  very high risk patients: LDL-C≥1.8mmol/L(70mg/dL)&#xD;
&#xD;
               -  high risk patients: LDL-C≥2.6mmol/L(100mg/dL)&#xD;
&#xD;
               -  moderate and low risk patients: LDL-C≥3.4mmol/L(130mg/dL)&#xD;
&#xD;
        4.Fasting triglycerides ≤4.5 mmol/L(400mg/dL);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of NYHA class III-IV heart failure or EF&lt;30%&#xD;
&#xD;
          2. History of uncontrolled arrhythmia within 3 months&#xD;
&#xD;
          3. History of MI,UA, PCI or CABG, stroke within 3 months.&#xD;
&#xD;
          4. History of DVT or pulmonary embolism within 3 months.&#xD;
&#xD;
          5. Planned cardiac surgery or revascularization.&#xD;
&#xD;
          6. Uncontrolled hypertension.&#xD;
&#xD;
          7. Uncontrolled diabetes mellitius (HbA1c&gt;8.0%）.&#xD;
&#xD;
          8. Other conditions that the researchers considered inappropriate to participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, Doctor of Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of the PLA Northern Theater Command</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaofang Lai</last_name>
    <phone>86 13640203214</phone>
    <email>xiaofang_lai@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiyan Chen, Doctor of Medicine</last_name>
      <phone>(020) 8382 7812</phone>
      <email>chen-jiyan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing People's Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163316</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianyou Ji, Masterof Medicine</last_name>
      <phone>0459-6612000</phone>
      <email>jixianyou@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijun Huang, Doctor of Medicine</last_name>
      <phone>0731-88618339</phone>
      <email>mhzj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical University (Affiliated Hospital of Xuzhou Medical College)</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhu, Master of Medicine</last_name>
      <phone>0516-85802369</phone>
      <email>hongzhumao@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of the PLA Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaling Han, Doctor of Medicine</last_name>
      <phone>024-28856123</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

